T follicular regulatory cells suppress Tfh-mediated B cell help and synergistically increase IL-10-producing B cells in breast carcinoma

In this study, total circulating CD4 T cells were sorted into CD25+CXCR5− Treg-like, CD25+CXCR5+ Tfr-like, and CD25−CXCR5+ Tfh-like subsets. Data showed that the Tfr-like subset presented intermediate levels of both Foxp3 and Bcl-6, while the Treg-like subset was high in Foxp3 and low in Bcl-6, and the Tfh-like was high in Bcl-6 and low in Foxp3. Of note, the frequencies of Tfr-like and Treg-like cells were significantly elevated in breast cancer (BC) patients than in non-cancer (NC) controls. Tfr-like cells in BC patients also expressed significantly higher levels of Foxp3 than those in NC controls. Neither Treg-like nor Tfr-like cells could support Ig production from naive B cells, while Tfh-like cells potently supported Ig production from naive B cells. Tfr-like cells increased the availability of IL-10, both by directly producing IL-10 and by increasing IL-10 production from B cells. Interestingly, Tfr-like cells increased IL-10 production from B cells synergistically with Tfh cells, but at the same time, significantly reduced Ig production in the Tfh-B cell coculture. These Tfr-mediated effects on Tfh cells were not found in canonical Treg cells. Overall, this study demonstrates several distinctive features in circulating Tfr cells and suggests that Tfr cells may promote the formation of IL-10-producing B cells in BC.
Source: Immunologic Research - Category: Allergy & Immunology Source Type: research

Related Links:

Publication date: Available online 17 September 2019Source: SteroidsAuthor(s): Anjali Verma, Nofrat Schwartz, D. Joshua Cohen, Barbara D. Boyan, Zvi SchwartzAbstractLaryngeal squamous cell carcinoma (LSCC) has been shown to respond to 17β-estradiol. However, the presence and characterization of estrogen receptors (ER) and other sex hormone receptors in LSCC are still being determined. Sex hormone receptors and the way sex hormones impact LSCC tumors are important for understanding which patients would benefit from hormone therapies, such as anti-estrogen therapies. This information also has prognostic value, as there ...
Source: Steroids - Category: Drugs & Pharmacology Source Type: research
ConclusionsHigh CEL expression may be an independent prognostic factor for the poor survival of breast cancer.
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
This 61-year-old woman presented with new primary triple negative breast cancer (TNBC) in the lateral breast 10 years after completing radiation for ductal carcinoma in situ (DCIS) in the same breast.1 Despite neoadjuvant chemotherapy and mastectomy with only residual DCIS and negative nodes, patient developed a TNBC re-recurrence only 9 months later. She was treated with chemotherapy, and there remains positive residual localized disease by positron emission tomography (PET). At this point we recommend the following.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
The objective of this study was to re-evaluate CD205 co-expression with other MEC markers, such as p63 and CD10, in nonneoplastic and neoplastic breast tissue and to evaluate its pathological diagnostic utility in these types of breast cancer. MATERIAL AND METHODS: Nonneoplastic breast tissue samples with a terminal duct lobular unit and duct were obtained from fibroadenoma and mastopathy patients. Neoplastic breast tissue samples included ductal carcinoma in situ (DCIS) (n=43) and invasive ductal carcinoma (IDC) (n=60), including the tubule-forming type (n=20). These specimens were investigated by CD205, p63, and CD10...
Source: Histology and Histopathology - Category: Cytology Tags: Histol Histopathol Source Type: research
Alternative splicing of pre-mRNAs plays a pivotal role during the establishment and maintenance of human cell types. Characterizing the trans-acting regulatory proteins that control alternative splicing has therefore been the focus of much research. Recent work has established that even core protein components of the spliceosome, which are required for splicing to proceed, can nonetheless contribute to splicing regulation by modulating splice site choice. We here show that the RNA components of the spliceosome likewise influence alternative splicing decisions. Although these small nuclear RNAs (snRNAs), termed U1, U2, U4, ...
Source: Genome Research - Category: Genetics & Stem Cells Authors: Tags: RESEARCH Source Type: research
Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Breast Carcinoma Metastatic in the Bone;   HER2/Neu Negative;   Metastatic Breast Carcinoma;   Metastatic Triple-Negative Breast Carcinoma;   Prognostic Stage IV Breast Cancer AJCC v8 Interventions:   Drug: Paclitaxel;   Radiation: Radium Ra 223 Dichloride Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Breast Carcinoma;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Germlin e BRCA1 Gene Mutation;   Germline BRCA2 Gene Mutation;   HER2/Neu Negative;   Metastatic Breast Carcin...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Breast Carcinoma Metastatic in the Bone;   Metastatic Breast Carcinoma;   Metastatic Triple-Negative Breast Carcinoma;   Prognostic Stage IV Breast Cancer AJCC v8 Interventions:   Drug: Paclitaxel;   Radiation: Radium Ra 223 Dichloride Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Breast Carcinoma;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Germlin e BRCA1 Gene Mutation;   Germline BRCA2 Gene Mutation;   HER2/Neu Negative;   Metastatic Breast Carcin...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Breast Carcinoma Metastatic in the Bone;   HER2/Neu Negative;   Metastatic Breast Carcinoma;   Metastatic Triple-Negative Breast Carcinoma;   Prognostic Stage IV Breast Cancer AJCC v8 Interventions:   Drug: Paclitaxel;   Radiation: Radium Ra 223 Dichloride Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy & Immunology | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Study